1. Japan Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Taisho Pharmaceutical Holdings Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

TAIPY
Taisho Pharmaceutical Holdings Co., Ltd.US flagOther OTC
14.00
USD
+2.00
- -
18.13BMarket Cap
2011 Y
2012 Y
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
22,391,500,000
22,603,750,000
23,759,500,000
24,664,083,333.33
24,207,416,666.67
24,163,000,000
23,312,500,000
23,344,833,333.33
21,780,750,000
24,060,000,000
23,503,083,333.33
22,350,250,000
25,115,083,333.33
26,698,750,000
Basic EPS, GAAP
2,907,666,666.67
2,029,750,000
2,193,333,333.33
2,724,333,333.33
2,044,000,000
1,872,750,000
2,398,416,666.67
2,639,916,666.67
4,049,416,666.67
1,681,000,000
1,109,666,666.67
1,093,500,000
1,583,083,333.33
701,750,000
Free Cash Flow per Basic Share
3,211,583,333.33
1,041,083,333.33
2,384,250,000
3,781,083,333.33
2,329,166,666.67
2,903,666,666.67
2,603,000,000
2,903,250,000
1,192,333,333.33
2,739,250,000
2,304,500,000
1,176,416,666.67
-783,916,666.67
- -
Dividend per Share
635,250,000
618,750,000
738,166,666.67
741,166,666.67
741,666,666.67
741,916,666.67
664,500,000
730,916,666.67
731,083,333.33
798,833,333.33
732,250,000
617,916,666.67
683,833,333.33
- -
Book Value per Share
46,981,083,333.33
48,383,750,000
49,817,416,666.67
51,797,916,666.67
53,308,833,333.33
54,437,916,666.67
56,169,833,333.33
58,076,666,666.67
61,395,166,666.67
60,685,250,000
61,086,333,333.33
61,082,000,000
61,981,333,333.33
62,154,750,000
Tangible Book Value per Share
42,070,500,000
41,649,916,666.67
44,481,583,333.33
46,929,500,000
50,666,333,333.33
50,355,250,000
52,559,500,000
55,016,666,666.67
58,319,416,666.67
43,163,833,333.33
45,156,000,000
46,241,500,000
47,570,916,666.67
50,813,750,000
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
268,698
271,245
285,114
295,969
290,489
289,956
279,750
280,138
261,369
288,720
282,037
268,203
301,381
320,385
Operating Margin (%)
16.41
14.16
12.39
14.08
11.01
9.96
11.43
13.2
11.94
7.32
7.08
4.01
7.64
5.9
Depreciation Expense
12,455
12,078
12,054
12,387
12,938
12,473
11,670
11,380
11,290
17,020
22,041
23,074
24,648
- -
Net Income, GAAP
34,892
24,357
26,320
32,692
24,528
22,473
28,781
31,679
48,593
20,172
13,316
13,122
18,997
8,421
Effective Tax Rate (%)
32.47
41.26
36.17
33.72
35.11
33.31
28.01
30.58
22.73
27.69
33.87
30.13
27.78
36.1
Profit Margin (%)
12.99
8.98
9.23
11.05
8.44
7.75
10.29
11.31
18.59
6.99
4.72
4.89
6.3
2.63
Working Capital
173,311
171,476
191,492
204,995
224,851
253,024
250,849
295,862
411,328
289,167
300,065
316,587
302,102
335,953
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
535,231
538,667
578,156
611,931
653,240
643,126
665,086
691,316
724,135
739,777
758,404
767,957
809,343
857,295
Return on Invested Capital (%)
5.51
4.15
4.01
4.58
3.24
2.95
3.49
3.75
3.37
2.07
1.75
0.98
2.1
1.44
Return on Capital (%)
6.06
4.02
4.17
5.05
3.58
3.19
4.03
4.28
6.48
2.51
1.52
1.51
2.21
0.79
Return on Common Equity (%)
6.34
4.26
4.47
5.36
3.89
3.48
4.34
4.62
6.78
2.75
1.82
1.79
2.57
1.13

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
403,334
409,807
416,777
Cash, Cash Equivalents & STI
268,420
260,757
266,367
Accounts Receivable, Net
58,619
73,465
72,994
Inventories
58,319
62,773
63,939
Total Current Liabilities
79,508
79,600
80,824
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.45%
3.22%
5.39%
Free Cash Flow
-11.46%
-32.13%
-166.64%
Net Income, GAAP
3.32%
0.84%
44.77%
Sales/Revenue/Turnover
0.73%
1.78%
12.37%
Total Cash Common Dividend
-0.39%
-0.8%
10.67%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
63,884
66,277
69,890
68,152
268,203
2023
69,069
75,449
83,151
73,712
301,381
2024
80,802
82,295
83,576
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
98,250,000
- -
- -
- -
1,093,500,000
2023
479,250,000
- -
- -
- -
1,583,083,333.33
2024
363,583,333.33
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
617,916,666.67
2023
- -
- -
- -
- -
683,833,333.33
2024
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Akira Uehara
Full Time Employees
8,784
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
3-24-1 Takada Tokyo Japan 170-8655
IPO Date
Jan 8, 2021
CIK
0001716957
Website
taisho-holdings.co.jp
Similar Companies
JW Pharmaceutical Corporation (001060.KS)
Viyash Scientific Limited (VIYASH.NS)
North American Cannabis Holdings, Inc. (USMJ)
MC Endeavors, Inc. (MSMY)
Phoenix Life Sciences International Limited (PLSI)
Baijin Life Science Holdings Limited (MNNGF)
Business
Taisho Pharmaceutical Holdings Co., Ltd. (TAIPY) operates as a holding company for the Taisho Pharmaceutical Group, which engages primarily in the development, manufacture, and sale of over-the-counter (OTC) drugs, prescription pharmaceuticals, health foods, and supplements. The group offers core products including energy drinks such as Lipovitan D and Biopovitan; cough and cold remedies like Pabron, Fervex, and Vicks; pain relievers such as Tempra (paracetamol), Counterpain, Dafalgan, Efferalgan, and Biotadol; laxatives including Colac; hair growth treatments like RiUP (minoxidil); antibiotics such as Clarith (clarithromycin); gastrointestinal products like Biofermin; anti-inflammatory agents including LOQOA Tape and Nanozora (anti-TNFα nanobody); diabetes treatments such as Luseogliflozin (Lusefi); and visceral fat reducers like alli; alongside Kampo herbal medicines, eye drops (Biomieye), and other consumer health items under brands like UPSA. Founded in 1912 and headquartered in Toshima-ku, Tokyo, Japan, the company conducts operations principally in Japan, Southeast Asia (including Indonesia, Malaysia, Thailand, Vietnam via subsidiaries like PT Bristol-Myers Squibb Indonesia, Hoepharma Holdings, and Duoc Hau Giang Pharmaceutical), and Europe through its French subsidiary UPSA. Recent developments include the February 2025 partnership with Meiji Seika Pharma to jointly market the insomnia treatment vornorexant (Vornorexant) in Japan; a strategic collaboration and exclusive license agreement with Biolinq for Japan; the 2019 acquisition of UPSA from Bristol-Myers Squibb, enhancing its European pain relief and cold medicine portfolio; consolidation of Duoc Hau Giang Pharmaceutical JSC in Vietnam; launch of LOQOA Tape for osteoarthritis and Nanozora auto-injector in recent years; and earlier management buyout considerations in 2023-2024.